Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ACZ885 (canakinumab) for active rheumatoid arthritis reports results on efficacy, safety and tolerability; findings have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2013-06-19